Christopher J. Molloy, Ph.D., R.Ph., Senior Vice President

Christopher J. Molloy serves as the university’s senior vice president for research and economic development since 2013. His responsibilities include oversight and strategic planning for the university’s $650 million in annual research expenditures and management of the many institutional offices and resources that support Rutgers’ research and economic development activities.

Under Molloy’s leadership, the Office of Research and Economic Development (ORED) has expanded the university’s research innovation through patents, startups and the transfer of technologies to industry, including advanced internal translational research support in the life sciences and other critical research areas. ORED also works closely with other New Jersey universities, as well as various state and county organizations to promote economic development, increase public-private partnerships and attract new jobs to New Jersey.

Molloy joined Rutgers in 2007 as dean of the Ernest Mario School of Pharmacy. In 2011, he was appointed interim provost for biomedical and health sciences and successfully managed the complex integration of Rutgers and most of the former University of Medicine and Dentistry of New Jersey (UMDNJ) in 2013. Molloy then served as interim chancellor of Rutgers Biomedical and Health Sciences until joining ORED. 

Molloy received his bachelor’s degree in pharmacy from Rutgers and his doctoral degree from the joint Rutgers Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School/Graduate School–New Brunswick. He was a post-doctoral fellow at the National Cancer Institute.

Prior to joining Rutgers, Molloy held senior research and management positions at Johnson & Johnson, 3-Dimensional Pharmaceuticals Inc., and Bristol-Myers Squibb Pharmaceutical Research Institute. At Rutgers, he holds a faculty position as Distinguished Professor of Pharmacology and Toxicology and is a member of the Rutgers Cancer Institute of New Jersey, the American Association for Cancer Research, and the American Society for Biochemistry and Molecular Biology, and the American Pharmacists Association. He was elected as a Fellow of the American Association for the Advancement of Science in 2016.